About this episode
The episode discusses the future of cell therapy with insights from industry leaders on stem cells and manufacturing challenges.
In this episode of Denatured, you'll be hearing from Miguel Forte, president of the International Society for Cell and Gene Therapy (ISCT), and John Ellis, co-founder & CEO of Trenchant Bios, speaking live from the ISCT annual meeting. We dive into mesenchymal stem cells and induced pluripotent stem cells, exploring the science behind them, the manufacturing challenges, and the potential for scalable, engineered next-generation therapies. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Jon Ellis , Co-founder & CEO, Trenchant Bio Miguel Forte , President, International Society for Cell & Gene Therapy Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
People in this episode
Host: Jennifer C. Smith-Parker
Guests: John Ellis, Miguel Forte
Topics covered
- cell therapy
- mesenchymal stem cells
- induced pluripotent stem cells
- manufacturing challenges
- next-generation therapies
Keywords
- cell therapy
- mesenchymal stem cells
- induced pluripotent stem cells
- manufacturing
- gene therapy
Mentioned in this episode
Organizations: International Society for Cell and Gene Therapy, Trenchant Bios
More episodes of BioSpace
- Portugal, Spain and the new biotech frontier · June 10, 2026 · 21 min
- Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence · June 10, 2026 · 25 min
- Rethinking hair loss treatment · June 3, 2026 · 22 min
- ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck · June 3, 2026 · 27 min
- France’s biotech ecosystem: science, capital and scale · May 28, 2026 · 21 min
- Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds · May 27, 2026 · 25 min
Explore listener stats, chart rankings, contacts and more on the BioSpace podcast page.